Prevents angina pectoris due to coronary artery disease. ANDA 75522, held by Dexcel Ltd. Isosorbide Mononitrate.
As of Nov 16, 2026, ANDA 75522 (Isosorbide Mononitrate), held by Dexcel Ltd, was first approved by FDA on Apr 17, 2000, with 12 approved supplements and 0 published complete response letters.
INDICATIONS & USAGE Isosorbide mononitrate extended-release tablets are indicated for the prevention of angina pectoris due to coronary artery disease. The onset of action of oral isosorbide mononitrate is not sufficiently rapid for this product to be useful in aborting an acute anginal episode.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 17, 2000 | Original application | Approved |
| Isosorbide Mononitrate60MG · tablet, extended release;oral | Isosorbide Mononitrate | Rx |
| Isosorbide Mononitrate30MG · tablet, extended release;oral | Isosorbide Mononitrate | Rx |
| Jul 14, 2025 | Supplement 31Labeling · Standard review | Approved | None posted |
| Jan 26, 2022 | Supplement 22Labeling · Standard review | Approved | None posted |
| Oct 31, 2014 | Supplement 12Manufacturing | Approved | None posted |
| Apr 29, 2011 | Supplement 11Labeling | Approved | None posted |
| Mar 24, 2004 | Supplement 9Labeling | Approved | None posted |
| Feb 19, 2002 | Supplement 8Labeling | Approved | None posted |
| Feb 19, 2002 | Supplement 7Manufacturing | Approved | None posted |
| Sep 26, 2001 | Supplement 6Manufacturing | Approved | None posted |
| Apr 4, 2001 | Supplement 5Labeling | Approved | None posted |
| Apr 4, 2001 | Supplement 4Manufacturing | Approved | None posted |
| Jan 8, 2001 | Supplement 1Manufacturing | Approved | None posted |
| Dec 22, 2000 | Supplement 3Labeling | Approved | None posted |
| Apr 17, 2000 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters